Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis
Status:
Unknown status
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
Study design is double-blind, randomized, placebo-controlled study in 3 parallel groups with
the use of active comparator and placebo. Total duration of therapy of about 2 years. Study
hypothesis is equivalence of efficacy and safety of the investigational drug BCD-033 original
drug Rebif®.